EPCORE trial data show epcoritamab plus lenalidomide and rituximab delivers responses in relapsed/refractory follicular lymphoma with outpatient dosing.
Uvette Lou, PharmD, BCOP
Advertisement
Articles by Uvette Lou, PharmD, BCOP
Peer Reviewed
This article reviews the efficacy and safety data for bispecific T-cell engagers and the practical considerations for their implementation across various types of practice sites for the historically difficult-to-treat relapsed/refractory B-cell lymphoma population.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
Brain Inflammation May Not Drive Persistent Long COVID Symptoms, New Imaging Study Finds
3
Subcutaneous Isatuximab On-Body Injector Shows High Reliability, Favorable Safety Across Multiple Myeloma Trials
4
Adults With Schizophrenia Remain Stable When Transitioning from Atypical Antipsychotic to Cobenfy
5